SALTEROL 250 DPI CAPS

Product Description

SALTEROL 250 DPI CAPS is a premium combination therapy formulated with Salmeterol 50mcg and Fluticasone Propionate 250mcg, designed to provide long-lasting relief from asthma and chronic obstructive pulmonary disease (COPD) symptoms. This dry powder inhalation (DPI) capsule ensures targeted pulmonary delivery for maximum respiratory efficacy.

Engineered to meet the highest GMP standards, SALTEROL 250 is ideal for hospitals, clinics, retail pharmacies, and bulk pharmaceutical procurement. Its dual-action formula offers both bronchodilation and anti-inflammatory benefits, making it a preferred choice for pulmonologists and respiratory care providers.

Key Benefits:

• Combines Salmeterol (a long-acting bronchodilator) and Fluticasone (a corticosteroid) for comprehensive respiratory management

• Provides 24-hour symptom control in asthma and COPD

• Ensures deep lung penetration via DPI technology for faster relief

• Ideal for chronic respiratory care protocols in hospitals and clinics

Applications:

• Maintenance therapy for moderate to severe asthma

• Long-term management of COPD with frequent exacerbations

• Widely prescribed in respiratory medicine, pulmonology, and primary care

Why Choose SALTEROL 250 DPI CAPS?

• Proven efficacy in airway inflammation and bronchospasm control

• Highly recommended for bulk orders, institutional supply, and third-party manufacturing

• Ready stock available for pan-India B2B distribution